Details for Patent: 9,388,416
✉ Email this page to a colleague
Which drugs does patent 9,388,416 protect, and when does it expire?
Patent 9,388,416 protects RYTELO and is included in one NDA.
This patent has forty-eight patent family members in nineteen countries.
Summary for Patent: 9,388,416
| Title: | Modified oligonucleotides for telomerase inhibition |
| Abstract: | Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. |
| Inventor(s): | Gryaznov Sergei, Pongracz Krisztina |
| Assignee: | |
| Application Number: | US14720467 |
|
Patent Claim Types: see list of patent claims |
Recent additions to Drugs Protected by US Patent 9,388,416
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geron | RYTELO | imetelstat sodium | POWDER | 217779 | Jun 6, 2024 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-3956 | TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 9,388,416
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geron | RYTELO | imetelstat sodium | POWDER;INTRAVENOUS | 217779-001 | Jun 6, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA | ⤷ Sign Up | ||||
| Geron | RYTELO | imetelstat sodium | POWDER;INTRAVENOUS | 217779-002 | Jun 6, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,388,416
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004271215 | ⤷ Sign Up | |||
| Australia | 2009222616 | ⤷ Sign Up | |||
| Brazil | PI0414222 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
